Literature DB >> 12825172

Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection.

Ming-Lung Yu1, Chia-Yen Dai, Shinn-Cherng Chen, Chao-Chin Chiu, Li-Po Lee, Zu-Yau Lin, Ming-Yuh Hsieh, Liang-Yen Wang, Wan-Long Chuang, Wen-Yu Chang.   

Abstract

To investigate the influence of immunogenetics on response to interferon (IFN)-alpha treatment, human leukocyte antigen alleles were characterized in 100 unrelated Taiwanese patients with chronic hepatitis C virus (HCV) infection. A11, B51, Cw15, and DRB1*15 were positively correlated with sustained response, whereas A24 was inversely associated with response to IFN-alpha, after adjustment for cirrhosis, pretreatment virus load, and viral genotype. Homozygote-genotype analysis showed that A24 and DQB1*05 probably had gene-dosage effect on sustained response. DRB1*15 was in strong linkage disequilibrium with DQB1*05 and DQB1*06, but only haplotype DRB1*15-DQB1*05 was associated with response to IFN-alpha. Haplotype A11-DRB1*15 was strongly associated with sustained response. This suggests a role for a complex host-immunogenetics interplay in the response to IFN-alpha, in patients with chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825172     DOI: 10.1086/375554

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C.

Authors:  Venessa Pattullo; E Jenny Heathcote; David K H Wong
Journal:  Hepatol Int       Date:  2010-08-08       Impact factor: 6.047

2.  A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.

Authors:  Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Nai-Jen Hou; Li-Po Lee; Ming-Yen Hsieh; Chang-Fu Chiu; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Wen-Yu Chang; Wan-Long Chuang
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

3.  Relationship of human leukocyte antigen class II genes with the susceptibility to hepatitis B virus infection and the response to interferon in HBV-infected patients.

Authors:  Yong-Nian Han; Jin-Long Yang; Shui-Gen Zheng; Qun Tang; Wei Zhu
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

4.  Anti-SSB/La antibody is negatively associated with HLA-DR2 in chronic hepatitis C infection.

Authors:  Chien-Sheng Wu; Chung-Yi Hu; Ping-Ning Hsu
Journal:  Clin Rheumatol       Date:  2007-11-09       Impact factor: 2.980

5.  Evolution of interferon-based therapy for chronic hepatitis C.

Authors:  Chun-Hao Chen; Ming-Lung Yu
Journal:  Hepat Res Treat       Date:  2010-10-10

6.  Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.

Authors:  John E Tavis; Maureen J Donlin; Rajeev Aurora; Xiaofeng Fan; Adrian M Di Bisceglie
Journal:  Genome Med       Date:  2011-02-08       Impact factor: 11.117

Review 7.  Host factors determining the efficacy of hepatitis C treatment.

Authors:  Wan-Long Chuang; Ming-Lung Yu
Journal:  J Gastroenterol       Date:  2012-10-27       Impact factor: 7.527

8.  Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4.

Authors:  Olfat Shaker; Heba Bassiony; Maissa El Raziky; Samer S El-Kamary; Gamal Esmat; Akmal M El-Ghor; Mona M Mohamed
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

9.  Body mass index and nonresponse to antiviral treatment in korean patients with genotype 2 and 3 chronic hepatitis C.

Authors:  Yeon Joo Kim; Sung Bum Cho; Sang Woo Park; Hyoung Ju Hong; Du Hyeon Lee; Eun Ae Cho; Hyunsoo Kim; Sung Kyu Choi; Jong Sun Rew
Journal:  Chonnam Med J       Date:  2012-04-26

10.  Association between the HLA-DQB1 polymorphisms and the susceptibility of chronic hepatitis B: A comprehensive meta-analysis.

Authors:  Jinmei Huang; Liangshi Xiong; Jin Wang; Yongfang Liu; Qirong Zhu; Jun Lei; Zhonghui Zhou
Journal:  Biomed Rep       Date:  2016-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.